TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06148142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy based health promotion
Description: This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacy based health promotion
Description: This project will consist of three phases: baseline survey with first time intervention implementation; second intervention at 6 months; and third, end-line survey at 12 months. As part of the intervention within the randomized selected groups, the CP will conduct two 15-30 minute sessions throughout the intervention period, once at the baseline or first visit (T0) and once at the sixth month (T1). Patients will attend the two sessions at the pharmacies where they collect their prescription medication. Face-to-face counselling sessions will be held about hypertension and its management, including lifestyle changes and drug compliance.
Study: NCT06394843

Intervention type: OTHER
Intervention: Ultrafiltration
Description: Patients are selected depending on need of ultrafiltration

Intervention type: OTHER
Intervention: Ultrafiltration
Description: Patients are selected depending on need of ultrafiltration
Study: NCT05082064

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium

Intervention type: DIAGNOSTIC_TEST
Intervention: arterial blood gases and serum electrolytes
Description: arterial bloog gases parameters serum potassium serum sodium serum calcium
Study: NCT05641974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helpers Stay Quit Training
Description: The Helpers Stay Quit training emphasizes a tobacco-user centered, non-confrontational approach to encouraging others to quit smoking. Helpers Stay Quit trainees learn how to offer a 4-step helping conversation. The four steps of a helping conversation parallel the 4 core training modules of Helpers Stay Quit (Awareness, Understanding, Helping, Relating). A key learning objective of Helpers Stay Quit, is for Helpers to learn how to manage their own expectations for the process and outcome of a helping conversation (e.g. Helpers are taught that they cannot make anyone quit, but they can offer non-judgmental support, and information about effective cessation aids). Consequently, Helpers are taught to manage their own behavior when helping others (e.g. avoiding nagging or pushing a tobacco-user to quit). The helping conversation focuses on encouraging behavior change that is aligned with the tobacco user's current willingness/readiness to take any action toward quitting.
Study: NCT05276882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: It will be an individualized hypnosis session of Ericksonian type. It consists in going through 3 phases: induction, dissociation, suggestion.~The principle is to focus the patient's attention by talking to her or by surprising her, or by making her do an incongruous gesture which will make her focus on a restricted idea. She will reduce her field of consciousness and concentrate. This is where her work will begin, allowing her unconscious to function in order to find her solutions. At this moment, she is particularly receptive to suggestions and the hypnotherapist accompanies and guides her thoughts and her associations of ideas on therapeutic paths. He provokes a unique personal work which aims to promote healing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre-surgery consultation
Description: Dialogue with the patient to clarify her expectations.~* Answers to the patient's questions~* Precision on the organization of the hospitalization if necessary~* Information on the postoperative period with postural advice to facilitate the first getting up with less discomfort, and postures promoting rest in the postoperative period~* Information on relaxation techniques and their interest (abdominal breathing)
Study: NCT04919863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTP42:KVA4
Description: Single ascending dose (SAD) or multiple ascending dose (MAD) of NTP42:KVA4 administered to healthy volunteers as an oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, matched to corresponding doses of NTP42:KVA4 administered to healthy volunteers as an oral solution.
Study: NCT05295238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compass Course
Description: An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
Study: NCT05061186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistive Expiratory muscle Training Group
Description: Mild Resistive Expiratory Technique \[Expiratory Muscle Strength Training (EMST150)- six-week training protocol approximately 20 min per day\] The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for six weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Breathing Exercise Group
Description: Breathing Exercises: (approximately 20 minutes per day)~● Pursed lip breathing: (Sit with your back straight. Inhale through your nose for two seconds. Purse your lips like you're blowing on hot food and then breathe out slowly, taking twice as long to exhale as you took to breathe in. 4-5 times a day)~● Diaphragmatic breathing: (Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs. Breathe in slowly through your nose Tighten your stomach muscles, letting them fall inward as you exhale through pursed lips. Practice this exercise 5-10 minutes about 3-4 times per day).~● Incentive spirometer: (Hold in an upright position. Breathe in slowly and as deeply as possible. Hold your breath as long as possible (at least for 5 seconds). Then exhale slowly Rest for a few seconds and at least 10 times every hour)
Study: NCT06152952

Intervention type: PROCEDURE
Intervention: The rhomboid flap approach
Description: The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed

Intervention type: PROCEDURE
Intervention: The rhomboid flap approach
Description: The rhomboid flap Approach :~The flap will be dissected deep to the gluteal fascia (subfascial level) so as to raise thick a fasciocutaneous flap. This will assure good vascularity of the flap without dead space. The rhomboid flap (CDEF) will be mobilized from the gluteal fascia and sutured without tension in three layers~The deep suturing approach :~A vertical elliptical incision encompassing all pilonidal pits will be made and excision of the sinus will be carried out down to the level of the sacrococcygeal fascia. T then the deep fascia will be approximated and the wound will be closed
Study: NCT05665114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QN-030a
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: Lympho-conditioning Agent
Study: NCT06283576

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy
Description: Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for ground truth
Study: NCT04863222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: During a patients procedure, one tooth will receive Biodentine instead of MTA.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: During a patients procedure, one tooth will receive Biodentine instead of MTA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mineral trioxide aggregate (MTA)
Description: mineral trioxide aggregate (MTA)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mineral trioxide aggregate (MTA)
Description: mineral trioxide aggregate (MTA)
Study: NCT05135052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhenium-SCT
Description: Rhenium-SCT irradiation device
Study: NCT05845307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTI-101
Description: Given by PO
Study: NCT05100355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological serum injection
Description: In case of lack of CVC blood return, Physiological serum is injected in the CVC after Chest X-Ray

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast agent injection
Description: In case of lack of CVC blood return, Contrast agent is injected in the CVC after Chest X-Ray
Study: NCT04739527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCP-001
Description: allogeneic dendritic cell vaccine
Study: NCT06210438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921 + Bevacizumab
Description: SHR-A1921 + Bevacizumab
Study: NCT04881630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Mobile Contingency Management (CM)
Description: Financial incentives contingent upon smoking abstinence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Description: Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (SC)
Description: Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)
Study: NCT04873765

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgastrim Megalabs
Description: Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgastrim Megalabs
Description: Administration of 6 mg of Pegfilgrastim Megalabs subcutaneous single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgastim Amgen
Description: Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgastim Amgen
Description: Administration of 6 mg of Pegfilgrastim Amgen subcutaneous single dose
Study: NCT05827835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells injection
Description: CD7 CAR T cells treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: In this study, Allogeneic hematopoietic stem cell transplantation is used as a bridge therapy to CD7 CAR T cells infusion to treat patients with refractory or relapsed CD7 positive Malignant Hematologic Diseases
Study: NCT05506410

Intervention type: DRUG
Intervention: Rituximab
Description: Young patients (\< 65 years of age) were treated with R-BAP for 6 cycles (efficacy was assessed every 2 cycles, and adverse events were recorded), together with oral ibrutinib, followed by oral ibrutinib for 1 year after chemotherapy (efficacy was assessed every 3 months). Elderly patients (≥65 years of age) received 4 cycles of R-BAP (efficacy assessed every 2 cycles, and adverse reactions recorded), followed by 4 cycles of rituximab consolidation (efficacy assessed every 2 cycles) and 1 year of oral zanubrutinib (efficacy assessed every 3 months).
Study: NCT05795738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese character-based visuomotor training program
Description: this program includes visual-perceptual-motor play, paper-pencil activities, and ipad games using Chinese character as activity materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: traditional visuomotor training program
Description: this program includes play and paper-and-pencil activities, ipad games using commercial or self-designed stuffs as activity materials
Study: NCT04645810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Dose-Rate Brachytherapy
Description: High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
Study: NCT04730882

Intervention type: DIETARY_SUPPLEMENT
Intervention: Mixed Meal
Description: the meal will be 40% of each subject's daily estimated caloric need, with 50%, 30%, 20% from carbohydrates, fat and protein, respectively
Study: NCT04770649

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Any vaccine for COVID-19
Study: NCT05452135

Intervention type: OTHER
Intervention: Observation of visual, audotory and motor reaction time
Description: Visual, auditory and motor reaction time will be measured as a result of the measurements made during the dual task evaluation.
Study: NCT05024253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: . TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
Study: NCT04060316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-1200
Description: GLS-1200 is given as a nasal spray using an atomizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given as a nasal spray using an atomizer
Study: NCT05637619

Intervention type: DEVICE
Intervention: Monolithic Zirconia
Description: Maxillary or/and mandibular screw retained zirconia monolithic prostheses supported by at least 4 implants

Intervention type: DEVICE
Intervention: Hybrid-Acrylic
Description: Maxillary or/and mandibular screw retained hybrid prostheses supported by at least 4 implants;

Intervention type: BEHAVIORAL
Intervention: Dentate Patients
Description: Dentate Patients with natural dentition or tooth supported crowns
Study: NCT05541653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Well-being Interventions
Description: Tax preparation; access to public benefits; financial counseling and microgrants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Place-based Interventions
Description: Vacant lot greening; abandoned house remediation; trash cleanup; and tree planting.
Study: NCT06399809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be matched to the Fisetin intervention
Study: NCT05024253

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: mixture of sodium chloride (salt) and water in solution with 0.90% w/v of NaCl
Study: NCT06041009

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreatic elastase-1 in blood serum
Description: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreatic elastase-1 in blood serum
Description: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreatic elastase-1 in blood serum
Description: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreatic elastase-1 in blood serum
Description: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreatic elastase-1 in blood serum
Description: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pancreatic elastase-1 in blood serum
Description: Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.
Study: NCT05312840

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin / Carboplatin，Gemcitabine，Cindilimab
Description: 1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin / Carboplatin，Gemcitabine，Cindilimab
Description: 1. Routine dose group: Every three weeks as a cycle. On the first day of each cycle, Gemcitabine 1000mg / m2, Cisplatin 75mg / m2 / Carboplatin auc5 were injected intravenously, and Gemcitabine 1000mg / m2 and Cindilimab 200mg were injected intravenously on the eighth day; 2. Low dose group: every three weeks as a cycle. On the first day of each cycle, Gemcitabine 750mg / m2, Cisplatin 56mg / m2 / Carboplatin auc3 were injected intravenously 75. On the eighth day, Gemcitabine 750mg / m2 and Cindilimab 200mg were injected intravenously.
Study: NCT05278845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor
Study: NCT05252208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: Stretching (30-45 minutes, 5 days per week, 6 months)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Walking (30-45 minutes, 5 days per week, 6 months)
Study: NCT05318495

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy
Description: The Standard Colonoscope is a high-definition colonoscope employing advanced optical filtering and enhancement techniques - blue light imaging (BLI) and linked color imaging (LCI).